• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Document › Details

AstraZeneca plc. (2/2/18). "Press Release: Full-Year 2017 Results".

	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Product	Brilinta®
	Product 2	Farxiga®
	Person	Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“AstraZeneca’s revenues improved over the course of the year, a sign of how our company is steadily turning a corner. Strong commercial execution helped us bring our science to more patients, making the most of our exciting pipeline. We made encouraging progress across the main therapy areas and delivered strong growth in China.

Alongside our CVMD medicines Brilinta and Farxiga reaching blockbuster status, we launched our first Respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence. As well as bringing five new medicines to patients last year, we continued to find more potential uses for existing treatments, including Lynparza and Tagrisso.

We remain committed to our progressive dividend policy. Our strategy is working, propelled by a strong pipeline, good sales performance and continued cost discipline.”

Downloads

Full-Year 2017 Results announcement (PDF 1.6mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf ]

Full-Year 2017 Results investor presentation (PDF 4.4mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20investor%20presentation.pdf ]

Full-Year 2017 Clinical trials appendix (PDF 1.7mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20Clinical%20trials%20appendix.pdf ]

Record changed: 2018-02-08

Advertisement

More documents for AstraZeneca (Group)

• [1] Compugen Ltd.. (4/2/18). "Press Release: Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-specific and Multi-specific Antibody Products". Holon....
• [2] AstraZeneca plc. (2/28/18). "Press Release: MedImmune to Create Stand-alone Company for Early-stage Inflammation and Autoimmunity Biologics"....
• [3] AstraZeneca plc. (2/23/18). "Press Release: Lynparza Receives Positive EU CHMP Opinion in Platinum-sensitive Relapsed Ovarian Cancer"....
• [4] G1 Therapeutics, Inc.. (2/21/18). "Press Release: G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights". Research Triangle Park, NC....
• [5] AstraZeneca plc. (2/17/18). "Press Release: US FDA Approves Imfinzi for Unresectable Stage III Non-small Cell Lung Cancer"....
• [6] AstraZeneca plc. (2/15/18). "Press Release: Selumetinib Granted Orphan Drug Designation by the US FDA for Neurofibromatosis Type 1"....
• [7] Innate Pharma S.A.. (1/30/18). "Press Release: Innate Pharma and MedImmune Enter Clinical Trial Collaboration". Marseille....
• [8] Alligator Bioscience AB. (1/18/18). "Press Release: Alligator Bioscience Appoints New VP Business Development". Lund....
• [9] AstraZeneca plc. (1/12/18). "Press Release: Lynparza Approved by US FDA in Germline BRCA-mutated Metastatic Breast Cancer"....
• [10] AstraZeneca plc. (11/15/17). "Press Release: Faslodex Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib"....

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2018. Made in Germany.